ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1660

Prolactin Induces an Interferon Signature in Monocytes and Drives IRF1-HAT Interactions

Yiu Tak Leung1, Lihua Shi2, Kelly Maurer2, Li Song3 and Kathleen E. Sullivan4, 1Temple University, Philadelphia, PA, 2Immunology ARC 1216, The Children's Hospital of Philadelphia, Philadelphia, PA, 3Allergy Immunology, Children's Hospital of Philadelphia, Philadelphia, PA, 4Pediatrics, University of Pennsylvania, Philadelphia, PA

Meeting: 2017 ACR/ARHP Annual Meeting

Date of first publication: September 18, 2017

Keywords: Epigenetics, histone acetylation, interferons and prolactin, SLE

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Monday, November 6, 2017

Title: Systemic Lupus Erythematosus – Human Etiology and Pathogenesis Poster I

Session Type: ACR Poster Session B

Session Time: 9:00AM-11:00AM

Background/Purpose: Epigenetic changes in systemic lupus erythematosus (SLE) offer a potential explanation for the chronicity of disease. We previously found that interferon regulatory factor-1(IRF1) binding sites were highly enriched in histone H4 acetylation (H4ac) peaks in SLE monocytes. IRF1 directly interacts with histone-modifying enzymes. IRF1 is a downstream immune response mediator that plays an important role in the interferon (IFN) pathway. IRF1 is highly inducible by prolactin (PRL), a hormone implicated in the pathogenesis of SLE. PRL is involved in immune response modulation through the JAK/STAT/IRF1 pathway. Our studies extend this by defining a pivotal role for PRL in induction of histone modifying enzymes that alter the balance of histone acetylation and IRF1 activation and downstream chromatin effects.

Methods: Primary monocytes and THP-1 cells were treated with recombinant human PRL. Flow cytometry for H4ac were run on the Accuri C6 with isotype controls. Real-time quantitative reverse transcription polymerase chain reaction (qRT-PCR) evaluated the effects of PRL stimulation on expression of HATs/HDACs and interferon-response genes. Western blot, immunoprecipitation and ChIP assays defined PRL effects on HAT/HDAC protein expression and interactions with IRF1. IRF1 knockdown experiments were performed using a lentivirus system.

Results:

Flow cytometry found significantly increased total H4ac, H4K5, H4K8, H4K12, and H4K16 acetylation in primary monocytes stimulated by PRL.

qRT-PCR studies of HAT/HDAC expression patterns showed increases in PCAF, CBP, P300, GCN5 and ATF2 expression in THP-1 cells stimulated by prolactin that was time-dependent.

Western blot assays found that nuclear levels of IRF1, PCAF, p300, CBP, ATF2, TIP60, MOF and HBO1 increased with PRL stimulation; HDAC3 decreased with PRL stimulation.

IRF1 co-immunoprecipitation assays found IRF1-binding with PCAF, P300, CBP and ATF2 in both unstimulated and stimulated states. IRF1 interactions with p300, CBP and ATF2 increased at 1-2 hrs of PRL stimulation. ChIP assays revealed increased IRF1 binding to PRL-response genes TGFb and ID1; increased H4ac was seen at the promoter of ID1 with PRL stimulation.

IRF1 knock-down experiments validated that PRL effects on HATs are IRF1-dependent. PRL-induced increases in the gene expression of PCAF, CBP, ATF2 and TIP60 were abrogated in the IRF1 knock-down cells as compared to controls.

PRL effects on the IFN signature genes were defined by qRT-PCR. CXCL10, IFIT1, IFIT3, B2M, OAS1 and CD40 expression levels were significantly increased by 4-hrs of PRL stimulation. Longer exposure to PRL stimulation also found further significant increases in the expression of IFIT1, IFIT3, CXCL10, MX1, B2M, CD40, OAS1, OASL and NOD2 after 2 wks.

Conclusion: Prolactin has long been associated with autoimmunity. These studies provide key insights into the mechanisms. These data demonstrate that prolactin stimulation induces IRF1 activation and a pattern of acetylated H4 that corresponds to the changes seen in SLE. We found dominant effects at the level of epigenetics, an area not previously explored with respect to prolactin effects in autoimmunity.


Disclosure: Y. T. Leung, None; L. Shi, None; K. Maurer, None; L. Song, None; K. E. Sullivan, None.

To cite this abstract in AMA style:

Leung YT, Shi L, Maurer K, Song L, Sullivan KE. Prolactin Induces an Interferon Signature in Monocytes and Drives IRF1-HAT Interactions [abstract]. Arthritis Rheumatol. 2017; 69 (suppl 10). https://acrabstracts.org/abstract/prolactin-induces-an-interferon-signature-in-monocytes-and-drives-irf1-hat-interactions/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2017 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/prolactin-induces-an-interferon-signature-in-monocytes-and-drives-irf1-hat-interactions/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology